Together, our findings suggest that TMZ has substantial activity to attenuate the progression of RA by targeting TLR4/MYD88, which consequently leads to suppression of the associated downstream TRAF6/IRAK inflammatory pathway, suggesting its therapeutic potential as an antirhomboid drug. The gene discussed is IRAK1; the disease is rheumatoid arthritis.